CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 86 enrolled
Drug / intervention
pegaptanib sodiumdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00858208
NCT00858208N/ACompleted
CompareCT.gov

Long-Term Non-Interventional Study To Investigate The Efficacy And Safety Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice.

Pfizer·observational·Posted Mar 9, 2009·Updated Apr 11, 2012

In Brief

An observational study evaluating pegaptanib sodium for Neovascular Age-related Macular Degeneration. Completed, enrolled 86 participants across 8 sites.

Detailed Summary

Efficacy and safety of MACUGEN in patients suffering from neovascular age-related macular degeneration in routine clinical practice at least as good as demonstrated in randomized multicenter clinical trials.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNeovascular Age-related Macular Degeneration
CountriesGreece
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 9, 2009
Enrollment StartMar 1, 2008
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 17.3 years ago

Interventions

pegaptanib sodiumdrug

pegaptanib sodium intravitreal injection every 6 weeks for 2 years